ABS0155 @ #ACR23 Economic impact of switching from SQ MTX (Rasuvo) from oral MTX in U.S. RA pts?' ➡️ Rasuvo associated with significantly higher all cause total expenditure $4704 predominantly due to higher costs associated tin all cause pharmacy utilization $4,223! @Rheumnow https://t.co/ry8XxjvHRg